Global Peptide Cancer Vaccine market is expected to reach 1120 million US$ by the end of 2025
Published Date: 2019/2/27
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
With the ever increasing new cancer cases across the globe and the conventional treatment methods unable to cope up with the challenges posed by the tumor and their immune response evading techniques, cancer immunotherapy brings a ray of hope. Cancer immunotherapy allows the host's immune cells to get sensitized with the tumor-associated antigens which in turn elicits B cell and T cell mediated immune response to target and eliminate tumor cells. This is the underlying principle of cancer immunotherapy.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion in 2025 is about 40%.
The global Peptide Cancer Vaccine market is valued at 280 million US$ in 2018 is expected to reach 1120 million US$ by the end of 2025, growing at a CAGR of 22.2% during 2019-2025.
Click to view the full report: https://www.qyresearch.com/index/detail/958506/global-peptide-cancer-vaccine-market
Marketing: sales@qyresearchglobal.com
Media Contact: press@qyresearch.com
评论
发表评论